Adicet Bio (NASDAQ:ACET) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Adicet Bio (NASDAQ:ACET) in a report issued on Wednesday,Benzinga reports.

ACET has been the subject of several other reports. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of Adicet Bio in a research note on Thursday, November 7th. StockNews.com lowered Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.50.

Adicet Bio Price Performance

Shares of ACET stock opened at $1.01 on Wednesday. The company’s fifty day simple moving average is $0.96 and its two-hundred day simple moving average is $1.23. Adicet Bio has a 1 year low of $0.81 and a 1 year high of $3.62.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.34). Research analysts anticipate that Adicet Bio will post -1.39 EPS for the current year.

Institutional Investors Weigh In On Adicet Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in shares of Adicet Bio by 14.5% during the third quarter. Geode Capital Management LLC now owns 768,566 shares of the company’s stock valued at $1,107,000 after purchasing an additional 97,567 shares during the last quarter. RBF Capital LLC raised its stake in Adicet Bio by 62.5% during the third quarter. RBF Capital LLC now owns 601,135 shares of the company’s stock valued at $866,000 after buying an additional 231,135 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Adicet Bio by 790.1% in the second quarter. Cubist Systematic Strategies LLC now owns 409,049 shares of the company’s stock worth $495,000 after acquiring an additional 363,095 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Adicet Bio by 2,728.8% in the second quarter. Squarepoint Ops LLC now owns 362,230 shares of the company’s stock worth $438,000 after acquiring an additional 349,425 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Adicet Bio by 12.5% during the third quarter. XTX Topco Ltd now owns 292,180 shares of the company’s stock valued at $421,000 after acquiring an additional 32,392 shares in the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.